1. Medtech Insight
  2. >>Business
  3. >>R&D
  4. >>Clinical Trials

Talking ATTD, 780G, Rumors And Missteps With Medtronic’s Diabetes Leaders

 
• By Barnaby Pickering

Medtech Insight spoke to the president of Medtronic’s diabetes business, Que Dallara, as well as two of the company’s medical affairs directors, about the company’s recently published data, and the timeline for the US launch of its 780G system.

Blood Glucose
• Source: Shutterstock

The 12-month results from the ADAPT trial show how Medtronic’s 780G advanced hybrid closed loop continuous glucose monitoring system overcomes critical challenges faced by diabetes patients every day, Ohad Cohen, senior global medical affairs director for Medtronic’s diabetes division, told Medtech Insight.

Cohen presented the results at the 2023 Advanced Technologies & Treatments for Diabetes (ATTD) Conference in Berlin on 24 February. (Also see "News We're Watching: Renal Denervation Trial Highlights,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

FDA Halts Acceptance Of Chinese Lab Data Due To Accuracy Issues

 
• By Elizabeth Orr

The FDA has stopped accepting data from two Chinese labs due to accuracy issues. Mid-Link and SDWH have been flagged for potentially falsified results and other misconduct. This decision, which follows months of discussions and warnings, emphasizes the FDA's commitment to ensuring data integrity in medical device submissions.

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.